Neuroprotective effects of rotigotine in the acute MPTP-lesioned mouse model of Parkinson’s disease.
Neuroscience Letters. 2008-02-01; 432(1): 30-34
DOI: 10.1016/j.neulet.2007.12.001
Read on PubMed
1. Neurosci Lett. 2008 Feb 13;432(1):30-4. Epub 2007 Dec 8.
Neuroprotective effects of rotigotine in the acute MPTP-lesioned mouse model of
Parkinson’s disease.
Scheller D(1), Stichel-Gunkel C, Lübbert H, Porras G, Ravenscroft P, Hill M,
Bezard E.
Author information:
(1)SCHWARZ BIOSCIENCES GmbH, Alfred-Nobel Strasse 10, Monheim, Germany.
Dopamine agonists used to manage Parkinsonian motor symptoms have been suggested
to be neuroprotective. The study was designed to assess the neuroprotective
potential of the D(3)/D(2)/D(1) dopamine receptor agonist rotigotine in the acute
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned (MPTP) mouse model of
Parkinson’s disease by measuring mesencephalic degenerating neurons using
FluoroJade staining and the remaining dopaminergic nerve endings in the striatum
using dopamine transporter binding. Continuous administration of rotigotine at a
dose of 3mg/kg significantly attenuated MPTP-induced acute cell degeneration in
the FluoroJade-staining paradigm. Rotigotine (0.3-3mg/kg) partially protected
dopamine nerve endings from MPTP-induced degeneration in a dose-dependent manner.
These data suggest that rotigotine, at the doses employed, significantly
protected dopamine neurons from degeneration in an acute mouse model of MPTP
intoxication.
DOI: 10.1016/j.neulet.2007.12.001
PMID: 18162314 [Indexed for MEDLINE]